No Data
Are Poor Financial Prospects Dragging Down Sansure Biotech Inc. (SHSE:688289 Stock?
Guosen: AI technology drives precise diagnosis to achieve important breakthroughs.
The combination of AI and multi-omics is revolutionizing the fields of biomedicine and data science.
Sansure Biotech Inc. (688289.SH) plans to invest 0.13 billion yuan in Zhenmai Biotech to improve the Industry Chain layout in the field of Gene Sequencing.
Sansure Biotech Inc. (688289.SH) announced that the company plans to form a partnership with its related party Hunan Xiangjiang Sansure Biotech Inc. Fund...
Sansure Biotech Inc. (688289.SH): plans to jointly invest in Zhenmai Bio with a related party Fund.
On March 7, Gelonghui reported that Sansure Biotech Inc. (688289.SH) announced that in order to further implement the company's Global Strategy and improve the Industry Chain layout in the field of Gene Sequencing to maintain comprehensive competitiveness, the company held the second Board of Directors' fourth special meeting on March 7, 2025, to review and approve the proposal regarding the acquisition of partial equity in investee companies and the increase of capital, as well as joint investment with related parties. The company consented to jointly invest in Zhenmai Biotech with the related party’s industry Fund. Among them, the company invested a total of 0.13 billion yuan with its own funds through the acquisition of equity and capital increase Trade.
China Galaxy Securities: The AI Medical sector is experiencing a resurgence, with DeepSeek applications having a profound impact.
From the perspective of AI Medical applications, new drug development, equipment intelligence, diagnostic services, and Physical Examination services are expected to advance rapidly, promising to continuously enhance the valuation of the Medical Sector.
HAITONG SEC: The respiratory multiplex testing market is expected to continue expanding. It is recommended to pay attention to InnoTek (688253.SH) and others.
HAITONG SEC estimates that under neutral expectations, there will be a market space of 8.1 billion yuan for in-house respiratory testing products.